Assessing BioNTech (BNTX) Valuation After Prolonged Share Price Weakness And Loss Making Results

Recent stock performance and business snapshot

BioNTech (NasdaqGS:BNTX) stock has been under pressure recently, with the share price down about 3% over the past day, 5% over the past week and 13% over the past month.

Over the past 3 months, the stock has declined about 15%, with the year to date move down roughly 7%. Over the past year, the total return is a decline of about 3%.

Looking further back, the 3 year total return is down about 16%, and over 5 years the total return has fallen around 54%. These figures give a sense of how sentiment around BioNTech has shifted over time.

At the last close of US$89.55, BioNTech carried a market value of about US$22.6b. The company generated revenue of €2,805.2m and reported a net loss of €1,252.2m in its latest full year.

BioNTech focuses on immunotherapies, including BNT162, its mRNA vaccine for SARS-CoV-2, as well as a wide pipeline of oncology and infectious disease programs across late stage and earlier stage clinical trials.

See our latest analysis for BioNTech.

At the current share price of US$89.55, BioNTech’s weak 1 month and 3 month share price returns sit alongside a 1 year total shareholder return that is also slightly negative. This suggests momentum has been fading as investors reassess the company’s loss making financial profile and its broader pipeline beyond COVID-19 vaccines.

If you are weighing BioNTech’s recent pullback against other opportunities in healthcare, this could be a good moment to scan AI focused peers in the sector using our 32 healthcare AI stocks

With BioNTech now loss making and the stock down sharply from its multi year highs, the key question is whether the current valuation already reflects its vaccine comedown and pipeline risks, or whether the market is underestimating its future growth potential.

Most Popular Narrative: 82.1% Undervalued

Based on the most followed narrative, BioNTech’s fair value of $499.94 sits far above the last close at $89.55, setting up a very optimistic long term story.

"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles.

Sahin with his strength of pattern recognition and complexity reduction would certainly have started with an IT company, like many others. It is a stroke of luck that he has decided to fight against the Geissesl of humanity, because it is clear that medicine with AI, robotics and the breakdown of human metabolism into algorithms is facing a fundamental change.

Read the complete narrative.

The narrative, according to Hansimglueck, leans heavily on algorithm designed drug candidates, ambitious revenue assumptions and a profitability profile more often associated with mature platform companies.

Result: Fair Value of $499.94 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this bullish story still faces clear risks, including clinical trial setbacks for key oncology candidates and the company’s current loss making position of €1,252.2m.

Find out about the key risks to this BioNTech narrative.

Next Steps

Looking for more investment ideas?

If BioNTech’s story has you thinking more broadly about your portfolio, do not stop here. Widen your search and keep your watchlist working for you.

• Spot potential bargains early by checking out screener containing 21 high quality undiscovered gems that may not yet be crowded with attention.
• Prioritise resilience by reviewing 65 resilient stocks with low risk scores that score well on downside protection and stability factors.
• Target quality at a reasonable price by scanning 51 high quality undervalued stocks that combine solid fundamentals with appealing valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com